Zimmer Biomet Holdings, Inc. (ZBH)

Over the past six months, Zimmer Biomet's stock price has experienced a decline. In May 2025, despite beating Q1 2025 earnings estimates, the stock dropped after the company narrowed its 2025 EPS guidance. In July 2025, Zimmer Biomet's acquisition of Monogram Technologies led to an upgrade from Roth Capital Partners, while other analysts maintained a 'Hold' rating. In June 2025, Treace filed a patent infringement suit against Zimmer Biomet.

Zimmer Biomet's business experiences some seasonality. Demand typically declines during the summer months due to elective procedures and can increase at the end of the year as patients meet their annual deductibles on health insurance plans.

Zimmer Biomet Holdings, Inc. is a global medical technology company specializing in musculoskeletal healthcare, operating within the Health Technology sector. The company designs, manufactures, and markets a comprehensive portfolio of orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, office-based technologies, spine, craniomaxillofacial, and thoracic products, dental implants, and related surgical products. Major products include knee and hip replacement systems, craniomaxillofacial and thoracic products, spine products, sports medicine, biologics, extremities, and trauma products, dental implants, and robotic and digital technologies.

Zimmer Biomet operates globally with approximately 25 production sites worldwide and serves healthcare providers in over 100 countries. Its operations are segmented into three primary geographical regions: Americas, which includes the U.S. and other North, Central, and South American markets; Europe Middle East and Africa (EMEA), which includes key markets such as France, Germany, Italy, Spain, and the United Kingdom; and Asia Pacific, which covers key markets such as Japan, China, and Australia.

Zimmer Biomet generally maintains a strong brand reputation, consistently ranking among the top orthopedic medical device manufacturers. However, in the past year, certain events have impacted its reputation, including the CPT Hip System recall in July 2024, ongoing hip implant lawsuits, and a jury verdict in November 2023.

Zimmer Biomet Holdings, Inc. has a significant institutional ownership, with 87.19% of the company's shares held by institutional investors. Largest institutional shareholders include Vanguard Group Inc., Dodge & Cox, and BlackRock, Inc.